Denver, CO – May 1, 2014 -- Logan Collins, a junior at Boulder’s Fairview High School, was named winner of Colorado’s 2014 BioGENEius Challenge at a statewide competition held during April at the Colorado Science and Engineering Fair in Fort Collins.
The announcement is made by Colorado BioScience Association (CBSA) President & CEO April Giles, who says, “This is the first year for the competition in Colorado. We’re proud that Logan will represent our state and move on to compete against students from the U.S. and Canada at the International BioGENEius Challenge, held June 20-24 at the 2014 BIO International Convention in San Diego.”
The title of Collins’ presentation is: “The Conjugative Plasmid RK2 As a Delivery System for Artificial AnatheriaH Genes: A Novel Synthetic Biology Alternative to Traditional Antibiotics.” As the Colorado winner, Collins receives a travel stipend for the San Diego competition, along with one chaperone.
The first place winner in the International competition will receive a $7,500 cash prize, the second place winner will receive $5,000, the third place winner will receive $2,500 and the fourth place winner will receive $1,000.
The Challenge provides students with the biotechnology skills and knowledge needed to succeed in the Biotech Industry in the future. The competition is sponsored by Sanofi Pasteur, the vaccines division of leading global pharmaceutical company Sanofi, and Janssen Pharmaceutical Companies of Johnson & Johnson.
“Students are rapidly gaining interest in the sciences, and the BioGENEius Challenge has found a way to encourage those students who are excited about biotechnology to take the next step in their research,” said Mark Lievonen, President of Sanofi Pasteur Limited. “We are thrilled to participate in a program that cultivates young, innovative minds to address our global challenges in new ways.”
“Biotechnology offers an avenue to address some of the most pressing issues of our time. Through the BioGENEius Challenge students gain an appreciation for the fascinating aspects and tremendous potential of scientific experimentation,” added Jay P. Siegel, M.D., Chief Biotechnology Officer and Head of Scientific Strategy and Policy for Johnson & Johnson. “It is our expectation that this program will draw bright young people into the endeavor of biotechnology and help accelerate the development of the next-generation of scientists.”
In addition to Sanofi Pasteur and Janssen, support for the BioGENEius Challenge is provided by International Supporter: Genentech; and U.S. National Supporters: Acorda Therapeutics, The Allergan Foundation, Pfizer and Sangamo BioSciences.
Throughout the challenge, @BiotechInstitut will be tweeting interviews, photos, and engaging with the biotechnology community by using the hashtag #BioGENEius.
About the Biotechnology Institute
The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. Visit http://www.biotechinstitute.org.
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers a broad range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. Visit: http://www.sanofipasteur.com or http://www.sanofipasteur.us.
At Janssen we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Visit: http://www.janssenrnd.com.
About Colorado BioScience Association
CBSA is a not-for-profit organization providing services and support for Colorado's bioscience industry. With more than 350 members, CBSA actively works to promote the growth of the industry by advocating for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state, and speaking with a single voice on behalf of the industry. Visit http://www.cobioscience.com.
CBSA also is found on these social media sites:
Facebook Fan Page: http://www.facebook.com/ColoradoBioScienceAssociation
News Feed: http://coloradobio.blogspot.com
YouTube Channel: http://www.youtube.com/COBioscience